Rt Burge

Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025†

This study predicts the burden of incident osteoporosis‐related fractures and costs in the United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025. Total fractures were >2 million, costing nearly

One year outcomes and costs following a vertebral fracture

17 billion in 2005. Men account for >25% of the burden. Rapid growth in the disease burden is projected among nonwhite populations.

Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US

Vertebral fractures are believed to be important predictors for future vertebral and other fractures, leading to at least a 4- to 5-fold increase in the risk of subsequent fractures. However, little is known about their associated near-term costs. The purpose of this study was to quantify the subsequent fracture and cost outcomes emanating from patients with an incident vertebral fracture. A probabilistic decision analysis model was developed to estimate the expected cost of all subsequent fractures. We ran Kaplan-Meier time-to-event models on placebo patients in risedronate’s pivotal phase III clinical trial data to determine the cumulative incidence or probabilities of all fractures within one year of an incident vertebral fracture. Unit costs for health care payers in the USA and Sweden for vertebral, hip, other, and forearm/wrist fractures were multiplied by fracture probabilities to generate the expected costs of new fractures within one year of incident vertebral fractures. Our analysis found that that 26.1% of vertebral fracture patients with a mean age of 74 years refractured within 1 year (vertebral 17.4%; hip 3.6%; “other” 3.5%; forearm/wrist 1.6%). The calculated medical costs for those patients who refracture within 1 year was

The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

5906 and €3670 for the USA and Sweden, respectively, while the weighted average cost across all patients (refracture and non-fracture) within a year of their incident fracture was

Hospital care of osteoporosis-related vertebral fractures

1541 (USA) and €958 (Sweden). These results suggest that therapies with proven, rapid efficacy may offer important economic value to healthcare payers, providers and patients.

Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization.

Background: Osteoporosis is a condition marked by low bone mineral density and the deterioration of bone tissue. One of the main clinical and economic consequences of osteoporosis is skeletal fractures.Objective: To assess the healthcare and work loss costs of US patients with non-vertebral (NV) osteoporotic fractures.Methods: Privately insured (aged 18–64 years) and Medicare (aged ≥65 years) patients with osteoporosis (ICD-9-CM code: 733.0x) were identified during 1999–2006 using two claims databases. Patients with an NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib or hip) were matched randomly on age, sex, employment status and geographic region to controls with osteoporosis and no fractures. Patient characteristics and annual healthcare costs were assessed over the year following the index fracture for privately insured (n = 4764) and Medicare (n = 48 742) beneficiaries (Medicare drug costs were estimated using multivariable models). Indirect (i.e. work loss) costs were calculated for a subset of privately insured, employed patients with available disability data (n = 1148). All costs were reported in

Interstate Variation in the Burden of Fragility Fractures

US, year 2006 values.Results: In Medicare, mean incremental healthcare costs per NV fracture patient were

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia

US13 387 (

PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDINGTO NATIONAL LIPID TREATMENT GUIDELINES

US22 466 vs

PCV31 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR STANDARD FENOFIBRATE THERAPY

US9079; p < 0.05). The most expensive patients had index fractures of the hip, multiple sites and femur (incremental costs of